AFFINITY BIOSENSORS LLC
Affinity Biosensors’ LifeScale platform delivers rapid, high-throughput phenotypic antimicrobial susceptibility testing in under four hours, empowering clinical labs to make timely antibiotic decisions and combat drug-resistant infections.
Funding history
About AFFINITY BIOSENSORS LLC
How much funding has AFFINITY BIOSENSORS LLC raised?
AFFINITY BIOSENSORS LLC has raised $48.5M in total funding. The most recent round was Series A.
Where is AFFINITY BIOSENSORS LLC headquartered?
AFFINITY BIOSENSORS LLC is headquartered in Santa Barbara, CA.
What does AFFINITY BIOSENSORS LLC do?
Affinity Biosensors’ LifeScale platform delivers rapid, high-throughput phenotypic antimicrobial susceptibility testing in under four hours, empowering clinical labs to make timely antibiotic decisions and combat drug-resistant infections.
What problem does AFFINITY BIOSENSORS LLC solve?
Clinicians need fast, accurate antibiotic susceptibility test results -- especially for dangerous resistant Gram-negative bacteria in positive blood cultures -- to act quickly on patient treatment.
What's AFFINITY BIOSENSORS LLC's solution?
LifeScale, a rapid AST (antibiotic susceptibility testing) system using population-profiling technology with automated sample inoculation, incubation, reading, and reporting, delivering results in about 4.5 hours.
What makes AFFINITY BIOSENSORS LLC different?
FDA-cleared (a third clearance is cited), with published accuracy data benchmarked against standard-of-care methods (WalkAway, Phoenix, Vitek) and under 10 minutes of added hands-on technician time.
What makes AFFINITY BIOSENSORS LLC notable?
Affinity Biosensors was co-founded by MIT professor Scott Manalis, known for his microfluidic mass-sensing research, along with CEO Dr. Ken Babcock.
Leadership
❝ Cite this page
Free to use in articles, research, and reference works. Stable URL, will not change. Data on this page last updated August 26, 2026.